Skip to main content
SpringerLink
Log in

Acute Graft-vs-Host Disease

  • Chapter
Stem Cell Transplantation for Hematologic Malignancies

Part of the book series: Contemporary Hematology ((CH))

Abstract

Hemopoietic stem cell transplantation (HSCT) involves the transfer of cells that produce hemopoietic and lymphoid progeny. For donor cells to accept the host environment as “self ” requires that newly developing alloreactive T lymphocytes and mature donor T lymphocytes contained in the transplant inoculum be eliminated or inactivated, and only cells tolerant to the new self be permitted in order to prevent an adverse graft-vs-host (GVH) reaction. Multiple interactions between donor and host cells take place that contribute to the manifestations of this GVH reaction, leading to the clinical picture of GVH disease (GVHD).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. van Bekkum DW, de Vries MJ. Radiation Chimaeras. London: Logos, 1967.

    Google Scholar 

  2. Billingham RE. The biology of graft-versus-host reactions. In: The Harvey Lectures. New York: Academic, 1966: 21–78.

    Google Scholar 

  3. Hess AD. The immunobiology of syngeneic/autologous graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd ed., revised and expanded. New York: Marcel Dekker, 1997: 561–586.

    Google Scholar 

  4. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  PubMed  CAS  Google Scholar 

  5. Sullivan KM. Acute and chronic graft-versus-host disease in man [review]. Int J Cell Cloning 1986; 4 (suppl 1): 42–93.

    Article  PubMed  Google Scholar 

  6. Chao NJ, Deeg HJ. In vivo prevention and treatment of GVHD. In: Ferrara JLM, Deeg HJ, Burakoff S, eds. Graft-vs.-Host Disease, 2nd ed., revised and expanded. New York: Marcel Dekker, 1997: 639–666.

    Google Scholar 

  7. Ringd6 O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff S, eds. Graft-vs.-Host Disease, 2nd ed., revised and expanded. New York: Marcel Dekker, 1997: 525–559.

    Google Scholar 

  8. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196–1201.

    Article  PubMed  CAS  Google Scholar 

  9. Sale GE, Shulman HM, Hackman RC. Bone marrow. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic Immunopathology, 2nd ed. New York: Raven, 1995: 435–453.

    Google Scholar 

  10. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforM cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001; 97: 2886–2895.

    Article  PubMed  CAS  Google Scholar 

  11. Tsukada N, Kobata T, Aizawa Y, et al. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 1999; 93: 2738–2747.

    PubMed  CAS  Google Scholar 

  12. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Heematol 1997; 97: 855–864.

    Article  CAS  Google Scholar 

  13. Martin P, Nash R, Sanders J, et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 1998; 21: 273–279.

    Article  PubMed  CAS  Google Scholar 

  14. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989; 4: 247–254.

    PubMed  CAS  Google Scholar 

  15. Martin PJ, Schoch G, Gooley T, et al. Methods for assessment of graft-versus-host disease [letter]. Blood 1998; 92: 3479–3481.

    PubMed  CAS  Google Scholar 

  16. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58: 437–442.

    Article  PubMed  CAS  Google Scholar 

  17. Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft versus host disease. Blood 1995; 86: 4422–4429.

    PubMed  CAS  Google Scholar 

  18. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    PubMed  CAS  Google Scholar 

  19. Saurat JH, Gluckman E, Bussel A, et al. The lichen planus-like eruption after bone marrow transplantation. Br J Dermatol 1975; 93: 675–681.

    Article  PubMed  CAS  Google Scholar 

  20. Siimes MA, Johansson E, Rapola J. Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting [letter]. Lancet 1977; 2: 831–832.

    Article  PubMed  CAS  Google Scholar 

  21. Hood AF, Soter NA, RappeportJ, et al. Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation. Arch Dermatol 1977; 113: 1087–1091.

    Article  PubMed  CAS  Google Scholar 

  22. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    PubMed  CAS  Google Scholar 

  23. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267–276.

    PubMed  CAS  Google Scholar 

  24. Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461–466.

    PubMed  CAS  Google Scholar 

  25. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLAidentical sibling bone marrow transplantation. Blood 1990; 75: 2459–2464.

    PubMed  CAS  Google Scholar 

  26. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  PubMed  CAS  Google Scholar 

  27. Roca J, Granena A, Rodriquez-Roison R, et al. Fatal airway disease in an adult with chronic graft-versus-host disease. Thorax 1982; 37: 77–78.

    Article  PubMed  CAS  Google Scholar 

  28. Wyatt SE, Nunn P, Hows JM, et al. Airways obstruction associated with graft-versus-host disease after bone marrow transplantation. Thorax 1984; 39: 887–894.

    Article  PubMed  CAS  Google Scholar 

  29. Ralph DD, Springmeyer SC, Sullivan KM, et al. Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease. Am Rev Respir Dis 1984; 129: 641–644.

    PubMed  CAS  Google Scholar 

  30. Sullivan KM. Graft-versus-host-disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Boston: Blackwell Science, 1999: 515–536.

    Google Scholar 

  31. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft versus host disease after bone marrow transplantation. Blood 1989; 74: 1428–1435.

    PubMed  CAS  Google Scholar 

  32. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562.

    PubMed  CAS  Google Scholar 

  33. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  PubMed  CAS  Google Scholar 

  34. Ferrara IL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease [review]. Biol Blood Marrow Transplant 1999; 5: 347–356.

    Article  PubMed  CAS  Google Scholar 

  35. Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459–467.

    Article  PubMed  CAS  Google Scholar 

  36. Xun CQ, Tsuchida M, Thompson JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation. Transplantation 1997; 64: 297–302.

    Article  PubMed  CAS  Google Scholar 

  37. Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    PubMed  CAS  Google Scholar 

  38. Hill GR, Ferrara IL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [review]. Blood 2000; 95: 2754–2759.

    PubMed  CAS  Google Scholar 

  39. Cooke K, Olkiewicz K, Clouthier S, et al. Critical role for CD14 and the innate immune response in the induction of experimental acute graft-versus-host disease. Blood 2001; 98 (suppl 1): 776a, [Abstract #3229].

    Google Scholar 

  40. Janossy G, Bofill M, Poulter LW, et al. Separate ontogeny of two macrophage-like accessory cell populations in the human fetus. J Immunol 1986; 136: 4354–4361.

    PubMed  CAS  Google Scholar 

  41. Hakim FT, Mackall CL. The immune system: effector and target of graft-versus-host disease. In: FerraraJLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd ed., revised and expanded. New York: Marcel Dekker, 1997: 257–290.

    Google Scholar 

  42. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415.

    Article  PubMed  CAS  Google Scholar 

  43. Korngold R, Sprent J. Murine models for graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Boston: Blackwell Science, 1999: 296–304.

    Google Scholar 

  44. Baker MB, Riley RL, Podack ER, et al. Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci USA 1997; 94: 1366–1371.

    Article  PubMed  CAS  Google Scholar 

  45. Graubert TA, DiPersio JF, Russell JH, et al. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997; 100: 904–911.

    Article  PubMed  CAS  Google Scholar 

  46. Hiroyasu S, Shiraishi M, Koji T, et al. Analysis of Fas system in pulmonary injury of graft-versus-host disease after rat intestinal transplantation. Transplantation 1999; 68: 933–938.

    Article  PubMed  CAS  Google Scholar 

  47. Mori T, Nishimura T, Ikeda Y, et al. Involvement of Fas-mediated apoptosis in the hematopoietic progenitor cells of graft-versus-host reaction-associated myelosuppression. Blood 1998; 92: 101–107.

    PubMed  CAS  Google Scholar 

  48. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998; 91: 4051–4055.

    PubMed  CAS  Google Scholar 

  49. Jiang Z, Podack E, Levy RB. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 2001; 98: 390–397.

    Article  PubMed  CAS  Google Scholar 

  50. Taylor PA, Lees CJ, Blazer BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 3493–3499.

    Article  PubMed  CAS  Google Scholar 

  51. Buhlmann JE, Gonzalez M, Ginther B, et al. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 1999; 162: 4373–4376.

    PubMed  CAS  Google Scholar 

  52. Saito K, Sakurai J, Ohata J, et al. Involvement of CD40 ligand-CD40 and CTLA4–B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. Jlmmunol 1998; 160: 4225–4231.

    CAS  Google Scholar 

  53. Tsukada N, Akiba H, Kobata T, et al. Blockade of CD134 (0X40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 2000; 95: 2434–2439.

    PubMed  CAS  Google Scholar 

  54. Zhou P, Szot G, Guo Z, et al. Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig. Transplant Proc 2001; 33: 214–216.

    Article  PubMed  CAS  Google Scholar 

  55. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versushost disease. Eur J Immunol 1993; 23: 333–337.

    Article  PubMed  CAS  Google Scholar 

  56. De Wit D, Van Mechelen M, Zanin C, et al. Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993; 150: 361–366.

    PubMed  Google Scholar 

  57. Kataoka Y, Iwasaki T, Kuroiwa T, et al. The role of donor T cells for target organ injuries in acute and chronic graft-versus-host disease. Immunology 2001; 103: 310–318.

    Article  PubMed  CAS  Google Scholar 

  58. Ellison CA, Bradley DS, Fischer JM, et al. Murine graft-versus-host disease induced using interferon-gammadeficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia. Immunology 2002; 105: 63–72.

    Article  PubMed  CAS  Google Scholar 

  59. Rus V, Svetic A, Nguyen P, et al. Kinetics of Th l and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 1995; 155: 2396–2406.

    PubMed  CAS  Google Scholar 

  60. Ochs LA, Blazar BR, Roy J, et al. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant 1996; 17: 1085–1092.

    PubMed  CAS  Google Scholar 

  61. Chen F, Maldonado MA, Madaio M, et al. The role of host (endogenous) T cells in chronic graft-versus-host autoimmune disease. J Immunol 1998; 161: 5880–5885.

    PubMed  CAS  Google Scholar 

  62. Ferrara JL, Krenger W. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines [review]. Transfusion Med Rev 1998; 12: 1–17.

    Article  CAS  Google Scholar 

  63. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986; 136: 3543–3548.

    PubMed  CAS  Google Scholar 

  64. Ilan Y, Gotsman I, Pines M, et al. Induction of oral tolerance in splenocyte recipients toward pretransplant antigens ameliorates chronic graft versus host disease in a murine model. Blood 2000; 95: 3613–3619.

    PubMed  CAS  Google Scholar 

  65. Ordemann R, Hutchinson R, Friedman J, et al. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 2002; 109: 1249–1256.

    PubMed  CAS  Google Scholar 

  66. Shustov A, Nguyen P, Finkelman F, et al. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFNgamma production. J Immunol 1998; 161: 2848–2855.

    PubMed  CAS  Google Scholar 

  67. Dune FH, Aruffo A, Ledbetter J, et al. Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J Clin Invest 1994; 94: 1333–1338.

    Article  Google Scholar 

  68. Tamada K, Tamura H, Flies D, et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002; 109: 549–557.

    PubMed  CAS  Google Scholar 

  69. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol 1994; 153: 4040–4047.

    PubMed  CAS  Google Scholar 

  70. Okamoto I, Kohno K, Tanimoto T, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol 2000; 164: 6067–6074.

    PubMed  CAS  Google Scholar 

  71. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  PubMed  CAS  Google Scholar 

  72. Krenger W, Snyder KM, Byon JC, et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585–593.

    PubMed  CAS  Google Scholar 

  73. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  PubMed  CAS  Google Scholar 

  74. Schmitz N, Beksac M, Hasenclever D, et al. A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients (pts) with leukemia. Blood 2000; 96 (Pt 1): 481a [Abstract 2068].

    Google Scholar 

  75. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.

    PubMed  CAS  Google Scholar 

  76. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685–3691.

    PubMed  CAS  Google Scholar 

  77. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565–1577.

    Article  PubMed  CAS  Google Scholar 

  78. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997; 337: 373–381.

    Article  PubMed  CAS  Google Scholar 

  79. Broxmeyer HE, Smith FO. Cord blood stem cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation, 2nd ed. Boston: Blackwell Science, 1999: 431–443.

    Google Scholar 

  80. Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. NEngl JMed 1989; 321: 1174–1178.

    Article  CAS  Google Scholar 

  81. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157–166.

    Article  PubMed  CAS  Google Scholar 

  82. Apperley JF. Umbilical cord blood progenitor cell transplantation. The International Conference Workshop on Cord Blood Transplantation, Indianapolis, November 1993 [see comments]. Bone Marrow Transplant 1994; 14: 187–196.

    Google Scholar 

  83. Miscia S, Di Baldassarre A, Sabatino G, et al. Inefficient phospholipase C activation and reduced Lck expression characterize the signaling defect of umbilical cord T lymphocytes. Jlmmunol 1999; 163: 2416–2424.

    CAS  Google Scholar 

  84. Petersdorf E, Anasetti C, Servida P, et al. Effect of HLA matching on outcome of related and unrelated donor transplantation therapy for chronic myelogenous leukemia [review]. Hematol-Oncol Clin North Am 1998; 12: 107–121.

    Article  PubMed  CAS  Google Scholar 

  85. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001; 112: 988–994.

    Article  PubMed  CAS  Google Scholar 

  86. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001; 345: 1794–1800.

    Article  PubMed  CAS  Google Scholar 

  87. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999; 5: 243–252.

    Article  PubMed  CAS  Google Scholar 

  88. Sullivan KM, Deeg HJ, Sanders J, et al. Hyperacute graft-vs-host disease in patients not given immunosuppression after allogeneic marrow transplantation [concise report]. Blood 1986; 67: 1172–1175.

    PubMed  CAS  Google Scholar 

  89. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br Haematol 1987; 67: 397–406.

    Article  CAS  Google Scholar 

  90. Hagglund H, Bostrom L, Ringden O, et al. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients. Transplant Proc 1994; 26: 1821–1822.

    PubMed  CAS  Google Scholar 

  91. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.

    Article  PubMed  CAS  Google Scholar 

  92. Remberger M, Storer B, Ringden O, et al. Association between pretransplant thymogloblulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002; 29: 391–397.

    Article  PubMed  CAS  Google Scholar 

  93. Bacigalupo A, Oneto R, Lamparelli T, et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001; 28: 1093–1096.

    Article  PubMed  CAS  Google Scholar 

  94. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    PubMed  CAS  Google Scholar 

  95. Dreger P, Schmitz N. Allogeneic transplantation of peripheral blood stem cells. Baillière’s Best Pract Clin Haematol 1999; 12: 261–278.

    Article  CAS  Google Scholar 

  96. Bensinger WI, Clift R, Martin P, et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794–2800.

    PubMed  CAS  Google Scholar 

  97. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disese after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465–1470.

    PubMed  CAS  Google Scholar 

  98. Holler E, Roncarolo MG, Hintermeier-Knabe R, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 237–241.

    Article  PubMed  CAS  Google Scholar 

  99. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associated with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941–3946.

    PubMed  CAS  Google Scholar 

  100. Middleton PG, Taylor PRA, Jackson G, et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92: 3943–3948.

    PubMed  CAS  Google Scholar 

  101. Cullup H, Dickinson AM, Jackson GH, et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001; 113: 807–813.

    Article  PubMed  CAS  Google Scholar 

  102. Bacigalupo A, Soracco M, Vassallo F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927–932.

    Article  PubMed  CAS  Google Scholar 

  103. Grumet FC, Hiraki DD, Brown BWM, et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 2001; 7: 503–512.

    Article  PubMed  CAS  Google Scholar 

  104. Balduini CL, Frassoni F, Noris P, et al. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. Br J Haematol 2001; 114: 951–953.

    Article  PubMed  CAS  Google Scholar 

  105. Broers AEC, van der holt R, van Esser JWJ, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240–2245.

    PubMed  CAS  Google Scholar 

  106. Clark RE, Hermans J, Madrigal A, et al. HLA-A3 increases and HLA-DR1 decreases the risk of acute graftversus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. Br J Haematol 2001; 114: 36–41.

    Article  PubMed  CAS  Google Scholar 

  107. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221–3227.

    Article  PubMed  CAS  Google Scholar 

  108. Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269–2274.

    PubMed  CAS  Google Scholar 

  109. Arpinati M, Green CL, Heimfeld S, et al C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.

    PubMed  CAS  Google Scholar 

  110. Ruutu T, Volin L, Elonen E. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids. Transplant Proc 1988; 20: 491–493.

    PubMed  CAS  Google Scholar 

  111. Lnngvist B, Aschan J, Ljungman P, et al. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol 1990; 74: 547–548.

    Article  Google Scholar 

  112. Bacigalupo A, Maiolino A, Van Lint MT, et al. Cyclosporin A and chronic graft versus host disease. Bone Marrow Transplant 1990; 6: 341–344.

    PubMed  CAS  Google Scholar 

  113. Kansu E, Gooley T, Flowers MED, et al. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial [brief report]. Blood 2001; 98: 3868–3870.

    Article  PubMed  CAS  Google Scholar 

  114. Bostrth L, Ringd6 O, Gratama JW, et al. The impact of pretransplant herpesvirus serology on acute and chronic graft-versus-host disease. Transplant Proc 1990; 22: 206

    Google Scholar 

  115. Ljungman P, Niederwieser D, Pepe MS, et al. Cytomegalovirus infection after marrow transplantation for aplastic anemia. Bone Marrow Transplant 1990; 6: 295–300.

    PubMed  CAS  Google Scholar 

  116. Vogelsang GB. Advances in the treatment of graft-versus-host disease [review]. Leukemia 2000; 14: 509–510.

    Article  PubMed  CAS  Google Scholar 

  117. Uphoff DE. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc Soc Exp Biol Med 1958; 99: 651–653.

    PubMed  CAS  Google Scholar 

  118. Powles RL, Clink HM, Spence D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet 1980; 1: 327–329.

    Article  PubMed  CAS  Google Scholar 

  119. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graftversus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88: 3634–3641.

    PubMed  CAS  Google Scholar 

  120. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    PubMed  CAS  Google Scholar 

  121. Pai SY, Fruman DA, Leong T, et al. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood 1994; 84: 3974–3979.

    PubMed  CAS  Google Scholar 

  122. Vander Woude AC, Bierer BE. Immunosuppression and immunophilin ligands: cyclosporin A, FK506, and rapamycin. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease. New York, NY: Marcel Dekker, 1997: 111–149.

    Google Scholar 

  123. Hughes SE, Gruber SA. New immunosuppressive drugs in organ transplantation [review]. J Clin Pharmacol 1996; 36: 1081–1092.

    Article  PubMed  CAS  Google Scholar 

  124. Blazar BR, Taylor PA, Linsley PS, et al. In vivo blockade of CD28/CTLA4: B7/BB 1 interaction with CTLA4Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994; 83: 3815–3825.

    PubMed  CAS  Google Scholar 

  125. Lin H, Wei RQ, Gordon D, et al. Review of CTLA4Ig use for allograft immunosuppression. Transplant Proc 1994; 26: 3200–3201.

    PubMed  CAS  Google Scholar 

  126. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342–1348.

    PubMed  CAS  Google Scholar 

  127. Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors [review]. J Hematother Stem Cell Res 2000; 9: 299–306.

    Article  PubMed  CAS  Google Scholar 

  128. Schlegel PG, Aharoni R, Chen Y, et al. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo. [erratum appears in Proc Natl Acad Sci USA 1996;93(16):8796]. Proc Natl Acad Sci USA 1996; 93: 5061–5066.

    Article  PubMed  CAS  Google Scholar 

  129. Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453–463.

    PubMed  CAS  Google Scholar 

  130. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997; 158: 29–39.

    PubMed  CAS  Google Scholar 

  131. Blazar BR, Sharpe AH, Taylor PA, et al. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells. J Immunol 1996; 157: 3250–3259.

    PubMed  CAS  Google Scholar 

  132. Lu Y, Sakamaki S, Kuroda H, et al. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603. Blood 2001; 97: 1123–1130.

    Article  PubMed  CAS  Google Scholar 

  133. Cetkovic-Cvrlje M, Roers BA, Waurzyniak B, et al. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice. Blood 2001; 98: 1607–1613.

    Article  PubMed  CAS  Google Scholar 

  134. Townsend RM, Gilbert MJ, Korngold R. Combination therapy with a CD4–CDR3 peptide analog and cyclosporin A to prevent graft-vs-host disease in a MHC-haploidentical bone marrow transplantation model. Clin Immunol Immunopathol 1998; 86: 115–119.

    Article  PubMed  CAS  Google Scholar 

  135. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: arandomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–1334.

    PubMed  CAS  Google Scholar 

  136. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.

    PubMed  CAS  Google Scholar 

  137. Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 119–125.

    PubMed  CAS  Google Scholar 

  138. Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone vs cyclosporine A/prednisone. Transplant Proc 1987; 19: 2605–2607.

    PubMed  CAS  Google Scholar 

  139. Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1: 21–28.

    Google Scholar 

  140. Tollemar J, Ringd6 O, Heimdahl A, et al. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate. Transplant Proc 1988; 20: 470–479.

    PubMed  CAS  Google Scholar 

  141. Galimberti M, Polchi P, Lucarelli G, et al. A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia. Cyclosporine alone versus cyclosporine, cyclophosphamide, and methotrexate. Transplantation 1988; 45: 566–569.

    Article  PubMed  CAS  Google Scholar 

  142. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828–834.

    Article  PubMed  CAS  Google Scholar 

  143. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037–1045.

    PubMed  CAS  Google Scholar 

  144. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329: 1225–1230.

    Article  PubMed  CAS  Google Scholar 

  145. Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880–3887.

    PubMed  CAS  Google Scholar 

  146. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLAidentical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.

    PubMed  CAS  Google Scholar 

  147. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood 1998; 91: 3503–3508.

    PubMed  CAS  Google Scholar 

  148. Locatelli F, Bruno B, ZeccaM, et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 2000; 96: 1690–1697.

    PubMed  CAS  Google Scholar 

  149. Ruutu T, Volin L, Parkkali T, et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391–2398.

    PubMed  CAS  Google Scholar 

  150. Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Japanese FK506 BMT Study Group. Bone Marrow Transplant 2001; 28: 181–185.

    Article  PubMed  CAS  Google Scholar 

  151. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.

    PubMed  CAS  Google Scholar 

  152. Carlens S, Ringden O, Remberger M, et al. Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia. Transplant Proc 1997; 29: 3147–3149.

    Article  PubMed  CAS  Google Scholar 

  153. Sayer HG, Longton G, Bowden R, et al. Increased risk of infection in marrow transplant patients given methylprednisolone for graft-versus-host disease prevention. Blood 1994; 84: 1328–1332.

    PubMed  CAS  Google Scholar 

  154. Atkinson K, Biggs J, Concannon A, et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLAidentical sibling marrow transplantation for haematological malignancy. Aust NZ J Med 1991; 21: 850–856.

    Article  CAS  Google Scholar 

  155. Martin PJ, Kernan NA. T-cell depletion for GVHD prevention in humans. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd ed. New York: Marcel Dekker, 1997: 615–637.

    Google Scholar 

  156. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation [review]. Blood 2001; 98: 3192–3204.

    Article  PubMed  CAS  Google Scholar 

  157. Harris DT, Sakiestewa D, Lyons C, et al. Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow Transplant 1999; 23: 137–144.

    Article  PubMed  CAS  Google Scholar 

  158. van Dijk AM, Kessler FL, Stadhouders-Keet SA, et al. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 1999; 107: 169–175.

    Article  PubMed  CAS  Google Scholar 

  159. Fehse B, Frerk O, Goldmann M, et al. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 2000; 109: 644–651.

    Article  PubMed  CAS  Google Scholar 

  160. Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl JMed 1999; 340: 1704–1714.

    Article  CAS  Google Scholar 

  161. Yu X-Z, Martin PJ, Anasetti C. Role of CD28 in acute graft-versus-host disease. Blood 1998; 92: 2963–2970.

    PubMed  CAS  Google Scholar 

  162. Yu XZ, Bidwell SJ, Martin PJ, et al. CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564–4568.

    PubMed  CAS  Google Scholar 

  163. Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review [review]. Clin Infect Dis 1998; 27: 191–204.

    Article  PubMed  CAS  Google Scholar 

  164. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.

    PubMed  CAS  Google Scholar 

  165. Martin PJ, Rowley SD, Anasetti C, et al. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients. Blood 1999; 94: 2192 2199.

    Google Scholar 

  166. Nimer SD, Giorgi J, Gaj ewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation 1994; 57: 82–87.

    Article  PubMed  CAS  Google Scholar 

  167. Soiffer RJ, Weller E, Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versushost disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. [erratum appears in J Clin Oncol 2001;19(9):2583]. J Clin Oncol 2001; 19: 1152–1159.

    PubMed  CAS  Google Scholar 

  168. Truitt RL, Johnson BD, McCabe CM, et al. Graft versus leukemia. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft-vs.-Host Disease, 2nd ed., revised and expanded. New York: Marcel Dekker, 1997: 385–423.

    Google Scholar 

  169. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Med 2002; 8: 410–414.

    Article  PubMed  CAS  Google Scholar 

  170. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.

    Article  PubMed  CAS  Google Scholar 

  171. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med 2001; 7: 94–100.

    Article  PubMed  CAS  Google Scholar 

  172. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63–72.

    Article  PubMed  CAS  Google Scholar 

  173. Munshi NC, Govindaraj an R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89: 1334–1340.

    PubMed  CAS  Google Scholar 

  174. Bonini C, Ferrari G, Verzeletti S, et al. HS V-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719–1724.

    Article  PubMed  CAS  Google Scholar 

  175. Sykes M. Mixed chimerism and transplant tolerance [review]. Immunity 2001; 14: 417–424.

    Article  PubMed  CAS  Google Scholar 

  176. Storb R, Yu C, Wagner IL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054.

    PubMed  CAS  Google Scholar 

  177. Marts M, Niederwieser D, Sandmaier B, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood 2001; 98 (Pt 1): 858a [Abstract 3563].

    Google Scholar 

  178. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med 1983; 308: 302–307.

    Article  PubMed  CAS  Google Scholar 

  179. Heidt PJ, Vossen JM. Experimental and clinical gnotobiotics: influence of the microflora on graft-versus-host disease after allogeneic bone marrow transplantation [review]. J Med 1992; 23: 161–173.

    PubMed  CAS  Google Scholar 

  180. Beelen DW, Elmaagacli A, Muller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267–3275.

    PubMed  CAS  Google Scholar 

  181. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464–1472.

    PubMed  CAS  Google Scholar 

  182. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    PubMed  CAS  Google Scholar 

  183. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77: 1821–1828.

    PubMed  CAS  Google Scholar 

  184. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high-or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288–2293.

    PubMed  Google Scholar 

  185. McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115: 28–35.

    Article  PubMed  CAS  Google Scholar 

  186. Bertz H, Afting M, Kreisel W, et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999; 24: 1185–1189.

    Article  PubMed  CAS  Google Scholar 

  187. Ohashi Y, Minegishi M, Fujie H, et al. Successful treatment of steroid-resistant severe acute GVHD with 24h continuous infusion of FK506. Bone Marrow Transplant 1997; 19: 625–627.

    Article  PubMed  CAS  Google Scholar 

  188. Furlong T, Storb R, Anasetti C, et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985–991.

    Article  PubMed  CAS  Google Scholar 

  189. Mollee P, Morton AJ, Irving I, et al. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis [erratum appears in Br J Haematol 2001;115(1):235]. Br J Haematol 2001; 113: 217–223.

    Article  PubMed  CAS  Google Scholar 

  190. Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61–65.

    Article  PubMed  CAS  Google Scholar 

  191. Benito AI, Furlong T, Martin PJ, et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924–1929.

    Article  PubMed  CAS  Google Scholar 

  192. Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974; 44: 57–75.

    Google Scholar 

  193. MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40–46.

    Article  PubMed  CAS  Google Scholar 

  194. Hsu B, May R, Carrum G, et al. Use of antithymocyte globulin for treatment of steroid-refractory acute graftversus-host disease: an international practice survey. Bone Marrow Transplant 2001; 28: 945–950.

    Article  PubMed  CAS  Google Scholar 

  195. Khoury H, Kashyap A, Brewster C, et al. Anti-thymocyte globulin (ATG) for steroid-resistant acute graftversus-host disease after allogeneic hematopoietic stem cell transplantation: a costly therapy with limited benefits. Blood 1999; 94 (suppl 1): 668a [Abstract 2962].

    Google Scholar 

  196. Martin PJ, Remlinger K, Hansen JA, et al. Seattle Marrow Transplant Team. Murine monoclonal anti-T cell antibodies for treatment of refractory acute graft-versus-host disease (GVHD). Transplant Proc 1984; 16: 1494–1495.

    PubMed  CAS  Google Scholar 

  197. Hebart H, Ehninger G, Schmidt H, et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15: 891–894.

    PubMed  CAS  Google Scholar 

  198. Przepiorka D, Phillips GL, Ratanatharathorn V, et al. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood 1998; 92: 4066–4071.

    PubMed  CAS  Google Scholar 

  199. Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody, ABX-CBL. Blood 2001; 98: 2052–2058.

    Article  PubMed  CAS  Google Scholar 

  200. Carpenter PA, Appelbaum FR, Corey L, et al. Ahumanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712–2719.

    Article  PubMed  CAS  Google Scholar 

  201. Hervd, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2receptor monoclonal antibody (B-B 10). Blood 1990; 75: 1017–1023.

    Google Scholar 

  202. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320–1327.

    PubMed  CAS  Google Scholar 

  203. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83–89.

    PubMed  CAS  Google Scholar 

  204. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47–49.

    Article  PubMed  CAS  Google Scholar 

  205. van Oosterhout YV, van Emst L, Schattenberg AV, et al. A combination of anti-CD3 and anti-CD7 ricin Aimmunotoxins for the in vivo treatment of acute graft versus host disease. Blood 2000; 95: 3693–3701.

    PubMed  CAS  Google Scholar 

  206. Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824–830.

    PubMed  CAS  Google Scholar 

  207. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431.

    PubMed  CAS  Google Scholar 

  208. Besnier DP, Chabannes D, MahéB, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64: 49–54.

    Article  PubMed  CAS  Google Scholar 

  209. Dall’Amico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97: 848–854.

    Article  PubMed  Google Scholar 

  210. Sullivan KM, Mori M, Witherspoon R, et al. Alternating-day cyclosporine and prednisone (CSP/PRED) treatment of chronic graft-vs-host disease (GVHD): predictors of survival. Blood 1990; 76 (suppl 1): 568a [Abstract].

    Google Scholar 

  211. Koc S, Leisenring W, Flowers MED, et al. Therapy of chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood, 2002; 100: 48–51.

    Article  PubMed  CAS  Google Scholar 

  212. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 1991; 23: 3225–3227.

    PubMed  CAS  Google Scholar 

  213. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med 1992; 326: 1055–1058.

    Article  PubMed  CAS  Google Scholar 

  214. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86: 3604–3609.

    PubMed  CAS  Google Scholar 

  215. Koc S, Leisenring W, Flowers MED, et al. Thalidomide for treatment of patients with chronic graft-versushost disease. Blood 2000; 96: 3995–3996.

    PubMed  CAS  Google Scholar 

  216. Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001; 7: 265–273.

    Article  PubMed  CAS  Google Scholar 

  217. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807–811.

    Article  PubMed  CAS  Google Scholar 

  218. Aubin F, Humbert P. Immunomodulation induced by psoralen plus ultraviolet A radiation [review]. Eur J Dermatol 1998; 8: 212–213.

    PubMed  CAS  Google Scholar 

  219. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104.

    PubMed  CAS  Google Scholar 

  220. Socidl, Devergie A, Cosset JM, et al. Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49: 657–658.

    Article  PubMed  Google Scholar 

  221. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999; 24: 517–520.

    Article  PubMed  CAS  Google Scholar 

  222. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant 2000; 25: 1067–1071.

    Article  PubMed  CAS  Google Scholar 

  223. Basara N, Blau WI, Kiehl MG, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998; 30: 4087–4089.

    Article  PubMed  CAS  Google Scholar 

  224. Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73: 665–667.

    Article  PubMed  CAS  Google Scholar 

  225. Fontaine P, Roy-Proulx G, Knafo L, et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease [see comments.]. Nature Med 2001; 7: 789–794.

    Article  PubMed  CAS  Google Scholar 

  226. Ruggeri L, Capanni M, Urbani E, et al. Kir epitope incompatibility in the GvH direction predicts control of leukemia relapse after mismatched hematopoietic transplantation. Bone Marrow Transplant 2001; 27 (suppl 1): S11 [Abstract 0S78].

    Google Scholar 

Download references

Authors
  1. Uwe Platzbecker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Joachim Deeg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Platzbecker, U., Deeg, H.J. (2004). Acute Graft-vs-Host Disease. In: Soiffer, R.J. (eds) Stem Cell Transplantation for Hematologic Malignancies. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-733-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-733-8_7

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-6588-5

  • Online ISBN: 978-1-59259-733-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation